CN114423453A - 使用偶联的抗cd25酞菁和抗pd1的基于光化学的癌症疗法近红外(nir)光免疫疗法(pit) - Google Patents

使用偶联的抗cd25酞菁和抗pd1的基于光化学的癌症疗法近红外(nir)光免疫疗法(pit) Download PDF

Info

Publication number
CN114423453A
CN114423453A CN202080065407.6A CN202080065407A CN114423453A CN 114423453 A CN114423453 A CN 114423453A CN 202080065407 A CN202080065407 A CN 202080065407A CN 114423453 A CN114423453 A CN 114423453A
Authority
CN
China
Prior art keywords
tumor
cancer
conjugate
antibody
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080065407.6A
Other languages
English (en)
Chinese (zh)
Inventor
M·加西亚－古斯曼
R·海姆
J·方
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rakuten Medical Inc
Original Assignee
Rakuten Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rakuten Medical Inc filed Critical Rakuten Medical Inc
Publication of CN114423453A publication Critical patent/CN114423453A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080065407.6A 2019-07-30 2020-07-29 使用偶联的抗cd25酞菁和抗pd1的基于光化学的癌症疗法近红外(nir)光免疫疗法(pit) Pending CN114423453A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962880514P 2019-07-30 2019-07-30
US62/880,514 2019-07-30
US201962896453P 2019-09-05 2019-09-05
US62/896,453 2019-09-05
US201962931405P 2019-11-06 2019-11-06
US62/931,405 2019-11-06
PCT/US2020/043999 WO2021021882A1 (en) 2019-07-30 2020-07-29 Near-infrared (nir) photoimmunotherapy (pit) for the treatment of cancers using anti-cd25 antybody-phthalocyanine dye conjugate and anti-pd1 antibody

Publications (1)

Publication Number Publication Date
CN114423453A true CN114423453A (zh) 2022-04-29

Family

ID=72047165

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080065407.6A Pending CN114423453A (zh) 2019-07-30 2020-07-29 使用偶联的抗cd25酞菁和抗pd1的基于光化学的癌症疗法近红外(nir)光免疫疗法(pit)

Country Status (6)

Country Link
US (1) US20220313822A1 (https=)
EP (1) EP4004048A1 (https=)
JP (1) JP7627259B2 (https=)
CN (1) CN114423453A (https=)
TW (1) TW202118518A (https=)
WO (1) WO2021021882A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119564879A (zh) 2015-08-18 2025-03-07 乐天医药生技股份有限公司 用于光免疫疗法的组合物、联用及相关方法
AU2016308286B2 (en) 2015-08-18 2022-04-07 Rakuten Medical, Inc. Phthalocyanine dye conjugates and their storage
TW202133886A (zh) * 2019-12-06 2021-09-16 美商樂天醫藥生技股份有限公司 用於增強免疫及腫瘤治療之方法
WO2022182483A1 (en) * 2021-02-02 2022-09-01 Rakuten Medical, Inc. Methods for local and systemic treatment of cancers, tumors and tumor cells
CA3260932A1 (en) * 2022-06-30 2024-01-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services CD25-SPECIFIC ANTIBODIES AND THEIR USES
EP4662238A1 (en) * 2023-02-06 2025-12-17 F. Hoffmann-La Roche AG Combination therapy and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106470705A (zh) * 2014-08-08 2017-03-01 美国政府(由卫生和人类服务部的部长所代表) 在体内和在体外的靶标的光控移除
CN107929733A (zh) * 2011-07-11 2018-04-20 美国政府(由卫生和人类服务部的部长所代表) 光敏抗体‑荧光团缀合物
CN108136039A (zh) * 2015-08-18 2018-06-08 阿斯皮利安治疗学股份有限公司 用于光免疫疗法的组合物、联用及相关方法
CN108137701A (zh) * 2015-08-07 2018-06-08 美国政府(由卫生和人类服务部的部长所代表) 用于治疗癌症的针对抑制细胞的近红外光免疫疗法(nir-pit)
WO2019083971A1 (en) * 2017-10-23 2019-05-02 Children's Medical Center Corporation METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2740793C2 (ru) 2016-10-25 2021-01-21 Ракутен Медикал, Инк. Светорассеивающие устройства для использования в фотоиммунотерапии
US10416366B2 (en) 2016-10-25 2019-09-17 Rakuten Medical, Inc. Light diffusing devices for use in photoimmunotherapy
CA3096305A1 (en) * 2018-04-10 2019-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination of near infrared photoimmunotherapy targeting cancer cells and host-immune activation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107929733A (zh) * 2011-07-11 2018-04-20 美国政府(由卫生和人类服务部的部长所代表) 光敏抗体‑荧光团缀合物
CN106470705A (zh) * 2014-08-08 2017-03-01 美国政府(由卫生和人类服务部的部长所代表) 在体内和在体外的靶标的光控移除
CN108137701A (zh) * 2015-08-07 2018-06-08 美国政府(由卫生和人类服务部的部长所代表) 用于治疗癌症的针对抑制细胞的近红外光免疫疗法(nir-pit)
CN108136039A (zh) * 2015-08-18 2018-06-08 阿斯皮利安治疗学股份有限公司 用于光免疫疗法的组合物、联用及相关方法
WO2019083971A1 (en) * 2017-10-23 2019-05-02 Children's Medical Center Corporation METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HISATAKA KOBAYASHI: "Near-Infrared Photoimmunotherapy of Cancer", 《ACCOUNTS OF CHEMICAL RESEARCH》, vol. 52, no. 8, 23 July 2019 (2019-07-23), pages 2332 - 2339, XP055733438, DOI: 10.1021/acs.accounts.9b00273 *
TADANOBU NAGAYA: "Host Immunity Following Near-Infrared Photoimmunotherapy Is Enhanced with PD-1 Checkpoint Blockade to Eradicate Established Antigenic Tumors", 《CANCER IMMUNOLOGY RESEARCH》, vol. 7, no. 3, 31 March 2019 (2019-03-31), pages 401 - 413, XP055702485, DOI: 10.1158/2326-6066.CIR-18-0546 *

Also Published As

Publication number Publication date
WO2021021882A1 (en) 2021-02-04
JP7627259B2 (ja) 2025-02-05
US20220313822A1 (en) 2022-10-06
JP2022543765A (ja) 2022-10-14
TW202118518A (zh) 2021-05-16
EP4004048A1 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
CN114423453A (zh) 使用偶联的抗cd25酞菁和抗pd1的基于光化学的癌症疗法近红外(nir)光免疫疗法(pit)
US9132281B2 (en) Focused radiation for augmenting immune-based therapies against neoplasms
JP7579705B2 (ja) アンタゴニスト抗ｐｄ－１抗体による癌の治療方法
US20190365897A1 (en) Therapeutic compositions and related methods for photoimmunotherapy
US20240307541A1 (en) Methods for local and systemic treatment of cancers, tumors and tumor cells
JPWO2019189780A1 (ja) 癌の治療及び／又は予防用医薬組成物
CN111132696A (zh) Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途
CN115052631A (zh) 用于增强免疫及肿瘤治疗的方法
KR20080091427A (ko) 동시 화학요법 및 면역요법
US20220105182A1 (en) Radiotherapy improvements
US20220296712A1 (en) Methods for treatment using phthalocyanine dye-targeting molecule conjugates
WO2021182571A1 (ja) 癌の治療及び／又は予防のための医薬品
JP2020531437A (ja) ｈａＮＫセツキシマブ併用及び方法
CA2464947C (en) Combination therapy for treating disease
HK40092801A (zh) 用於治疗癌症的纳米颗粒组合物
JP2018533915A (ja) 抗ｆｕｇｅｔａｃｔｉｃ特性を有する改変されたナチュラルキラー細胞およびその使用
CN113952451A (zh) 一种治疗癌症的联合用药组合物及其应用
AU2002358246A1 (en) Combination therapy for treating disease
Schilsky Immunotherapy for colorectal cancer
JP2018527010A (ja) 抗ｆｕｇｅｔａｃｔｉｃ特性を有する改変されたＴ細胞およびその使用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
AD01 Patent right deemed abandoned

Effective date of abandoning: 20250516